Integrated biopharma inc (INB)
Income statement / Yearly
Jun'19Jun'18Mar'18Jun'17Mar'17Jun'16Jun'15Jun'14Jun'13Jun'12Jun'11
Sales, net

49,977

43,710

-

-

-

-

-

-

-

-

-

Sales, net

-

-

31,145

46,954

35,707

-

-

-

-

-

-

Cost of sales

43,755

38,722

27,623

40,287

30,747

-

-

-

-

-

-

Sales, net

-

-

-

-

-

42,214

37,488

33,683

33,623

36,604

40,665

Cost of sales

-

-

-

-

-

36,710

33,095

28,800

28,122

28,997

30,503

Gross profit

6,222

4,988

3,522

6,667

4,960

5,504

4,393

4,883

5,501

7,607

10,162

Selling and administrative expenses

3,518

3,294

2,453

3,480

2,603

3,390

3,460

3,531

4,385

8,113

10,524

Operating income

2,704

1,694

1,069

3,187

2,357

2,114

933

1,352

1,116

-506

-362

Other income (expense), net
Interest expense

630

926

694

911

684

953

979

964

979

1,109

1,938

Forbearance fees

-

-

-

-

-

-

-

-

-

1,100

-

Change in fair value of derivative liabilities

9

494

121

-427

-639

-64

705

-21

-133

9

-

Unrealized gain on investment

-23

-

-

-

-

-

-

-

-

-

-

Impairment on investment in iBio Stock

-

358

251

36

0

0

-

-

-

-

-

Impairment charge on investment in iBio, Inc.

-

-

-

-

-

-

-

-152

-139

-

-

Change in fair value of deriative instruments

-

-

-

-

-

-

-

-

-

-

-2

Other income, net

-18

101

13

43

41

92

210

5

245

4

37

Interest and investment income

-

-

-

-

-

-

-

-

-

-

5

Total other income

-

-

-

-

-

-

-

-

-

-

44

Other income (expense), net

-662

-689

-811

-1,331

-1,282

-925

-64

-1,132

-1,006

-

-1,894

Income before income taxes

2,042

1,005

258

1,856

1,075

1,189

869

220

-

-

-

Total other expense, net

-

-

-

-

-

-

-

-

-

-2,196

-

Income before income taxes

-

-

-

-

-

-

-

-

110

-2,702

-2,256

Provision for income taxes

354

326

397

-490

265

231

134

89

17

-

-

Income tax expense, net

-

-

-

-

-

-

-

-

-

-11

-25

Net income

1,688

679

-139

2,346

810

958

735

131

93

-2,713

-2,281

Change in fair value of derivative liability

-

-494

0

427

0

0

-705

0

-

-

-

Change in fair value of derivative liability

9

494

121

-427

-639

-64

-

-

-133

9

-

Interest expense, net of taxes

-

216

0

195

0

0

326

-

-

-

-

Amortization of prepaid financing costs, net of taxes

-

6

-

6

-

0

-

-

-

-

-

Accretion of Convertible debt

-

39

0

39

0

0

110

-

-

-

-

Diluted net income

1,688

446

-139

3,013

810

958

466

131

-

-

-

Basic earnings per common share (in dollars per share)

0.06

0.03

-0.01

0.11

0.04

0.05

0.03

0.01

0.00

-0.13

-

Diluted earnings per common share (in dollars per share)

0.06

0.02

-0.01

0.10

0.04

0.05

0.02

0.01

0.00

-0.13

-

Weighted average common shares outstanding - basic (in shares)

28,930

21,135

21,135

21,117

21,113

21,105

21,105

21,081

21,080

21,011

-

Add: Equivalent shares outstanding (in shares)

656

951

0

825

856

85

49

111

163

-

-

Shares issuable upon conversion of Convertible Debt - CD Financial, LLC (in shares)

-

8,230

0

8,230

0

0

8,230

-

-

-

-

Basic and diluted net income (loss) per common share (in Dollars per share)

-

-

-

-

-

-

-

-

-

-

-0.11

Weighted average common shares outstanding - diluted (in shares)

29,586

30,317

21,135

30,173

21,970

21,191

29,385

21,193

21,243

21,011

-

Weighted average common shares outstanding Basic and diluted (in Shares)

-

-

-

-

-

-

-

-

-

-

20,780